share_log

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20

HC Wainwright & Co.維持對Theravance Biopharma的買入,將目標股價提高至20美元
Benzinga ·  2023/05/09 06:41

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises the price target from $19 to $20.

HC Wainwright & Co. 分析師曹道格拉斯維持Theravance Biopharma(納斯達克股票代碼:TBPH)的買入,並將目標股價從19美元上調至20美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論